Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMT-191 in Adult Males With Classic Fabry Disease
NCT06270316Phase 2Recruiting
- Sponsor
- uniQure
- Start
- Jun 2024
- Primary completion
- Dec 2027
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
A Phase 2 trial of AMT-191 in Fabry disease (FD), sponsored by uniQure. Started Jun 2024; status: recruiting.
02
Drugs
AMT-191
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NCT06270316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06270316.